NEW
HAVEN, Conn., May 9, 2024
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in idiopathic pulmonary fibrosis (IPF)
and refractory chronic cough (RCC), today announced
that senior management will be attending investor, business
development and medical conferences in May and June.
The Citizens JMP Life Sciences Conference
May 13-14, 2024, New
York, NY
Corporate Presentation: May 14
at 12:00 p.m. ET
Trevi Presenter: Jennifer Good, President and CEO
ATS 2024 International
Conference
May 17-22, 2024, San Diego, CA
Session: A104: Advances in the Diagnosis and Treatment of
ILD
Abstract: Nalbuphine Extended-release Reduces Cough Bouts in
Patients With Idiopathic Pulmonary Fibrosis
Presentation: May 19,
3:00 p.m. - 4:15 p.m. PT
Location: San Diego
Convention Center, Room 33A-C (Upper Level)
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of
Respiratory Medicine at the University of Manchester, and an Honorary Consultant at
Manchester University NHS Foundation Trust. Director of the NIHR
Manchester Clinical Research Facility, Respiratory Theme Lead in
the NIHR Manchester Biomedical Research Centre and an NIHR Senior
Investigator.
Registration details: https://conference.thoracic.org/
Life Science Education Series: Chronic Cough – KOL Panel
Discussion
Discussion: May 20, 12:30 p.m. - 2:30 p.m. PT
Location: San Diego, CA
Panel Members: Experts in the field of chronic cough include
Professor Peter Dicpinigaitis,
Professor Jacky Smith, and Professor
Alyn Morice. Moderated by
Oppenheimer's Senior Biotechnology Analyst Dr. Leland Gershell.
To register, email: k.mcmanus@trevitherapeutics.com
2024 BIO International Convention
June 3-6, 2024, San
Diego, CA
Oppenheimer's 2024 Montauk Life Sciences
Summit
June 26-28, 2024,
Montauk, NY
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Trevi
is also developing Haduvio for prurigo nodularis. Haduvio is a dual
ĸ-opioid receptor agonist and µ-opioid receptor antagonist that
works both centrally in the brain as well as peripherally in the
lungs and has the potential for a synergistic antitussive effect to
treat chronic cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal relief to patients. RCC affects up to 10% of the adult
population, and Haduvio's expansion into RCC has the potential to
reach patients suffering from moderate to severe chronic cough.
There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the U.S. Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-conferences-302140439.html
SOURCE Trevi Therapeutics, Inc.